The therapeutic problem of proliferative diabetic retinopathy: Targeting somatostatin receptors

Hormone and Metabolic Research

Volumn 33, Issue 5, 2001, Pages 295-299

  Davis, M I ^a   Wilson, S H ^a   Grant, M B ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; Diabetic Retinopathy; Growth Hormone; Insulin Like Growth Factor; Octreotide; Somatostatin

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR;

CELL DEATH; CELL GROWTH; CELL PROLIFERATION; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; GROWTH HORMONE RELEASE; HORMONE INHIBITION; HUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; SHORT SURVEY; SIGNAL PROCESSING;

DIABETIC RETINOPATHY; HUMANS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 0034955429     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15286     Document Type: Short Survey

References (54)

1. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis
2. A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines
3. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells
4. Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: A primary role for tyrosine phosphatase SHP-1
5. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion form murine endothelial cell line (HECa10) culture
6. The effects of the somatostatin analog octreotide on angiogenesis in vitro
7. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995)
8. Effect of SMS 201-995 in rapidly progressive diabetic retinopathy
9. Effects of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: A pilot study
10. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995
11. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study
12. Essential role of growth hormone in ischemia-induced retinal neovascularization
13. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary hormone
14. Hypophysectomy: Transfrontal technique and results in the management of metastatic cancer and diabetic retinopathy
15. Ultrasonic selective hypophysectomy in Cushing's disease, acromegaly and diabetic retinopathy
16. Effect of one year continuous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus
17. Influence of thyroid hormones on somatostatin processing in cultured cerebro-cortical cells
18. Thyroid hormones regulate the expression of somatostatin receptor subtypes in the rat pituitary
19. Insulin-like growth factors: Studies in diabetes with and without retinopathy
20. Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes
21. Adenosine receptor activation induces vascular endothelial cell growth factor in human retinal endothelial cells
22. A two-year follow-up study of serum insulin-like growth factor-I in diabetics with retinopathy
23. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy
24. Rarity of diabetic retinopathy in patients with acromegaly
25. Diabetic retinopathy in acromegaly
26. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1
27. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry
28. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution
29. Influence of various administration routes on the antitumor efficacy of TT-232, a novel somatostatin analog
30. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity
31. Binding properties of somatostatin receptor subtypes
32. Subtype selectivity of peptide analogs for all fine cloned human somatostatin receptors (hsstr1-5)
33. Molecular biology of somatostatin receptors
34. Somatostatin receptor subtype specificity in human fetal pituitary culture
35. Selective stimulation of somatostatin receptor subtypes: Differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells
36. Design, synthesis, and biological activities of potent and selective somatostatin analogues incorporating novel peptoid residues
37. Nonpeptidyl somatostatin agonists demonstrate that sst2 and sst5 inhibit stimulated growth hormone secretion from anterior pituitary cells
38. Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells
39. Growth factors and diabetic retinopathy
40. Inhibition of IGF-1 and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide, a potential treatment for ocular neovascularization
41. Inhibitory effect of a long-acting somatotstatin analogue on EGF stimulated cell proliferation in Capan-2 cells
42. Modulation of Retinal Endothelial Cell Behavior by IGF-1 and Somatostatin Analogues: Implications for Diabetic Retinopathy
43. Molecular cloning and functional expression of a novel brain specific somatostatin receptor
44. Indentification of the subunits of GTP binding proteins coupled to somatostatin receptors
45. Subtype selectivity of peptide analogues for all five cloned human somatostatin receptors (hsstr1-5)
46. 1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase
47. Sst2 somatostatin receptor mediates cell cycle arrest and induction of p27 (Kip1). Evidence for the role of SHP-1
48. Regulation of acidification and apoptosis by SHP-1 and Bcl-2
49. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: Role of the phosphotyrosine phosphatase SHP-2
50. Activation in vitro of somatostatin receptor subtype 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: Coexpression with catalytically inactive SHP-2 blocks responsiveness
51. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells
52. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells
53. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3
54. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells